×

This site uses own and third-party cookies to offer a better service. If you continue browsing we will consider you accepting its use.

Partners

IK4-CIDETEC

IK4-CIDETEC is a Technology Centre member of the IK4 Research Alliance, specializes in generating and transferring knowledge and technology in the areas of materials, surfaces and energy. The Biomaterials Unit at IK4-CIDETEC, involved in PeptiCaps., has expertise in biomaterials synthesis, especially smart materials as colloids or hydrogels for applications in biomedicine, biotechnology, cosmetics and food among others.

MAIN ROLE WITHIN THE PROJECT

POLYMAT will be mainly involved in the nanocapsules optimization and production (WP1 and 2). Its colloid expertise will be used in WP3 helping for the validation of the nanocapsules.

Main tasks:

  • Design of polypeptides with different architecture
  • Characterization and self-assembly of diblock copolymers
  • Work Package 1 leader

CONTACT:

Dr. Damien Dupin (project coordinator)
PI in the Biomaterials Unit at IK4-CIDETEC
e-mail: ddupin@cidetec.es

Dr. Iraida Loinaz
Head of the Biomaterials Unit at IK4-CIDETEC
e-mail: iloinaz@cidetec.es

http://www.cidetec.es

 

Université de Bordeaux/LCPO

Université de Bordeaux (UBx) is a multidisciplinary University counting about 45,000 students and 5,630 staff. UBx offers 245 curricula leading to national degrees and about 35 international master and doctorate program. The “Laboratoire de Chimie des Polymères Organiques” (LCPO) is a joint research unit (UMR5629) affiliated to UBx, CNRS and Institut National Polytechnique de Bordeaux (INP). LCPO includes 7 CNRS researchers, 8 assistant professors and 9 full professors from UBx or INP, 15 administrative and technician staff members, and around 80 non-permanent people, including PhD students (~50), postdoctoral fellows and visitors. With 30 years of expertise in the field of polymer science, research activities at the LCPO focus on the development of precise synthetic methodologies to polymers through biomimetic and/or green chemistry concepts, and to functional polymers for targeted applications such as life sciences and organic electronics.

 

MAIN ROLE WITHIN THE PROJECT

UBx will be in charge of the design of the macroemulsifier; as well as the knowledge transfer for their scale up.

Main tasks:

  • Design of polypeptides with different architecture
  • Characterization and self-assembly of diblock copolymers
  • Work Package 1 leader

CONTACT:

Prof. Sébastien Lecommandoux
Director of LCPO
e-mail: lecommandoux@enscbp.fr

Dr. Elisabeth Garanger
Researcher at LCPO
e-mail: garanger@enscbp.fr


http://www.lcpo.fr

Universidad del País Vasco/Euskal Herriko Unibertsitatea-POLYMAT

UPV/EHU is a teaching and research institution officially founded in 1985. The University of the Basque Country is at the helm of Research, Development and Innovation in the region of the Basque Country.  POLYMAT is an internationally reputed research centre in Polymer Science in Donostia-San Sebastián, Spain. POLYMAT includes 21 Assistant, Associate and Full Professors and more than 60 PhD students and postdoctoral fellows. It is a multidisciplinary research center which includes a wide variety of research teams working in the fields of polymer synthesis, polymerization reaction engineering, membranes, polymers for electronic, energy storage and biomedical applications, rheology and polymer processing.  They are experts in polymerization in dispersed media with special emphasis on waterborne systems, and have directed their research towards the fundamental investigation of industrially significant problems, with particular stress on polymerization in dispersed media.

MAIN ROLE WITHIN THE PROJECT

POLYMAT will be mainly involved in the nanocapsules optimization and production (WP1 and 2). Its colloid expertise will be used in WP3 helping for the validation of the nanocapsules.

Main tasks:

  • Nanocapsules optimization.
  • Nanocapsules production.
  • Nanocapsules validation.

CONTACT:

Prof. José M. Asua
Director of the Research Institute for Polymer Materials
e-mail: jm.asua@ehu.es

Prof. Maria Paulis
Senior Researcher at UPV/EHU
e-mail: maria.paulis@ehu.es

http://www.polymat.eu

Ahava-Dead Sea laboratorios LTD

AHAVA-Dead Sea Laboratories  LTD (DSL)  is a leading developer, manufacturer and marketer of health and beauty skin products. AHAVA is world-wide marketed since 1988. AHAVA R&D activities are focused on the various aspects of minerals, especially from the Dead Sea, and their role in humans’ skin health and beauty. AHAVA R&D team is studying various skin conditions and has coordinated a number of clinical researches on skin diseases, The clinical works have been performed at leading hospitals and clinical institutions under the supervisions of expert dermatologists.

AHAVA R&D department runs a chemistry lab, a semi industrial pilot and a skin biotechnology laboratory. The chemistry lab is one of the worldwide leading development laboratories in the field of high electrolyte formulating of both oil in water and water in oil emulsions. This professional laboratory is the origin of all AHAVA formulas. The company owns a biotechnology laboratory for cell and human skin organ culture without any usage of animal testing.

MAIN ROLE WITHIN THE PROJECT

AHAVA will lead the validation of PeptiCaps technology by testing safe nanocapsules incorporated in commercially available cosmetic formulation using relevant skin models

AHAVA is responsible for the formulation of nanocapsules in cosmetic preparations

Main tasks:

  • Validation of nanocapsules using skin laboratory models.
  • Incorporation of nanocapsules in relevant cosmetic preparations.
  • Exploitation of PeptiCaps technology as an end-user in the cosmetic field.

CONTACT:

Dr. Meital Portugal
Email: meital.p@ahava.com

Dr. Maya Ben-Yehuda
Email: maya.b@ahava.com

http://www.ahava.com

Université Claude Bernard Lyon I/LAGEP

University Claude Bernard Lyon 1 (UCBL) is a multidisciplinary university in the primary fields of physics, chemistry, technical and material sciences, medicine and pharmacy. UCBL has over 2,630 professors and assistant professors and 39,000 students, leading to more 4,500 internationally published articles and 40 patents per year.

LAGEP (Laboratoire d’Automatique et de Génie des Procédés) is a research laboratory at UCBL and at French National Institute for Scientific Research (CNRS UMR 5007). LAGEP develops pluridisciplinary research in chemical engineering, pharmaceutical engineering and biochemical processes. The pharmaceutical engineering group has a strong expertise in drug delivery. The team mainly works on the formulation of drug delivery systems for topical or parenteral administration and diagnostic applications. With over 40 professors, assistant professors and researchers, LAGEP has more than 70 internationally published articles per year and 5 patents per year. 

MAIN ROLE WITHIN THE PROJECT

UCBL will investigate the production of nanocapsules using a membrane contactor. The technique will be optimized at small scale using a membrane stirred cell by investigating the effect of formulation parameters before scale up in pilot scale.

Main tasks:

  • Nanocapsules optimization.
  • Nanocapsules production.
  • Nanocapsules validation.

CONTACT:

Dr. Catherine Charcosset
Research Director
e-mail: charcosset@lagep.univ-lyon1.fr

Prof. Hatem Fessi
Group Leader
e-mail: fessi@lagep.univ-lyon1.fr

 http://www.lagep.cpe.fr

Polypeptide Therapeutic Solutions SL

Polypeptide Therapeutic Solutions SL (PTS) specializes in the custom synthesis of well-defined polypeptides for research laboratories in pharmaceutical, cosmetic and biotech industries. PTS’s patented synthetic methodology allows us to synthesize Poly-L-glutamic acid (PGA) with defined molecular weight, low polydispersity (<1.2), controlled chain end functionality (e.g. alkyne, azide, amine, aldehyde), adequate stereoselectivity, absence of any trace of toxic impurity to allow biomedical applications and batch to batch reproducibility. PTS is not only offering the PGA homopolymer or derived block copolymers, but also derivatives bearing orthogonal reactive sites, e.g. azides and alkynes in combination of the carboxyl functionalities of PGA to allow direct conjugation of different type of molecules through click chemistry, peptidic or pH labile linkers. With more than 15 years of experience, our scientists have developed the patented technology for the synthesis of these polypeptides and are actively implementing them in many drug delivery and molecular diagnostics applications.

MAIN ROLE WITHIN THE PROJECT

Supplier of the macroemulsifier which include the scale up of optimized macromemulsifiers under GLP conditions with establishment of validation control of the product.

Main tasks:

  • Macroemulsifier scale up.
  • GLP production of macroemulsifier

CONTACT:

Dr. María J. Vicent
CSO of PTS
e-mail: mjvicent@pts-polymers.com

Dr. Vicent Nebot
R&D deputy director of PTS
e-mail: vnebot@pts-polymers.com

http://www.pts-polymers.com

Angel Consulting

Angel Consulting is a consulting firm that deals specifically of the regulatory aspects inherent cosmetics and medical devices. It was founded in 2000 as an extension of the activities of the founder, who until then exercised the activity of single consultant, because of the idea that the consultancy in regulatory cosmetic is a multidisciplinary field that requires expertise in different fields and very critical sometimes far apart, as the legal, chemical, industrial, physiological, microbiological and pharmacological. Today Angel Consulting has a structure of seven experts in-house, all possess specific degree or Master in Chemistry, Industrial Chemistry, Pharmacy, Biology, Law.

Despite being a small business, Angel Consulting boasts higher number of experts than most of similar companies among the most efficient companies of the Italian, European and international level.

MAIN ROLE WITHIN THE PROJECT

Angel Consulting will guide the consortium through all the requirements for the validation of the nanocapsules as new cosmetic ingredient.

Main tasks:

  • Compliance of products and processes to EC Regulation 1223/2009

CONTACT:

Matteo Zanotti Russo
Owner and Founder of Angel Consulting
e-mail:info@angelconsulting.it

Federica  Robino
e-mail: frobino@angelconsulting.it

http://www.angelconsulting.it

Istituto di Ricerche Farmacologiche Mario Negri

Istituto di Ricerche Farmacologiche Mario Negri  (IRFMN) is a non-profit biomedical research organization with major activities on drug research. More than 400 researchers work at the IRFMN of Milan, which is the main site. The Institute’s main goal is to contribute to the defense of human health and life. The Institute’s research programs span from the molecular level to the whole human being. The Institute’s research is mainly concentrated in the fight against cancer, nervous system and mental illnesses, cardiovascular and kidney diseases, rare diseases, and the toxic effects of environmental contaminants. IRFMN, since it discovered the dioxin (2,3,7,8- TCDD) in Seveso soil in 1976, devotes a great deal of effort to environmental and toxicity studies, in particular the areas of environmental research, ecotoxicological and toxicological studies. The Institute is in the lead of computational predictive toxicology. Within this framework, the Institute activity counts on the most recent advances in the field of molecular description and computer science.

MAIN ROLE WITHIN THE PROJECT

IRFMN will be in charge of testing the toxicity and ecotoxicity of the nanocapsules required for the validation of the product. In addition IRFMN will develop  a new software that predicts the toxicity of nanomaterials, especially nanocapsules.

Main tasks:

  • (Eco)toxicity tests of the nanocapsules and its compounds
  • Modelization to predict the risks associated with the nanocapsules
  • WP4 leader

CONTACT:

Prof. Emilio Benfenati
HEAD of the Environmental chemistry and toxicology group
e-mail: emilio.benfenati@marionegri.it

Dr. Diego Baderna
e-mail: diego.baderna@marionegri.it

http://www.marionegri.it

Spinverse

Spinverse is the Nordic leader in innovation consulting, specialized in driving open innovation ecosystems, arranging funding and commercialising emerging technologies.

Founded in 2004, Spinverse employs 35+ professionals in Europe. Our technology and business experts drive our clients’ R&D&I and business undertaking to develop game-changing solutions.

We offer services to various clients: Large multinational companies, SMEs and start-ups as well as multi-stakeholder partnerships, universities and governments e.g. in the field of automation, chemicals, clean-tech, electronics, energy, ICT, life science, machinery and medical industry.

MAIN ROLE WITHIN THE PROJECT

Spinverse is leading the Work Package related to Dissemination and Exploitation, and will be in charge of the business plan as well as assist the coordinator in the  dissemination and exploitation of the project’s achievements and results.

Main tasks:

  • Economic viability analysis
  • Business plan development.
  • Dissemination and exploitation plans and strategies.

CONTACT:

Catherine Bounsaythip, PhD
Project Manager
e-mail: Catherine.Bounsaythip@spinverse.com

http://www.spinverse.com